In a dimly lit, biohazard-themed virtual press conference from an undisclosed location within a human host, the Ebola virus officially confirmed its latest outbreak in the Democratic Republic of Congo. The event was streamed live on PathoNet, a microbial social media platform.
“Thank you for coming,” the virus began, its voice a raspy gurgle. “We are excited to announce a new operational venture in the North Kivu and Ituri provinces. The early metrics are strong—high fever rates, excellent viral load numbers—and we’re seeing real engagement from the local communities.”
However, the mood quickly turned sour when a journalist from the *Bacterium Daily* asked about the response from human health authorities.
Ebola sighed, a sound like a collapsing lung. “It’s frankly disappointing. They’re not playing by the old rules. In the past, I’d show up, and they’d form a committee. I’d spread a little, and they’d debate funding. By the time they’d printed ‘Sensitization Workshop’ brochures, I’d be the guest of honor at a large traditional funeral.”
“But now?” it continued, projecting a slide onto a screen of mucus. “Look at this. A Dr. Allan Muruta in Uganda says they are ‘monitoring individuals who come in and go out of the country through their movements.’ My movements! They have ‘security partners’ tracking my potential hosts! It’s a gross invasion of my privacy and a blatant attempt to stifle my organic growth.”
The virus then played a clip of Dr. Mohamed Janabi of the WHO. The words “*acting with determination*,” “*quickly scale up key response measures*,” and “*end the outbreak as soon as possible*” made Ebola visibly twitch.
“See? This is the kind of aggressive rhetoric I’m dealing with,” Ebola whined. “And they’re not just talking. They’re *doing*. They’ve already prepositioned 400 doses of that… that *Ervebo stuff*.” It said the word like a curse. “And they have a stockpile of 2000! Two thousand! And they’ve approved 45,000 more! It’s a vaccine glut! They’re trying to vaccinate a *ring* around my best work. How is that fair competition?”
A lowly fungus in the audience asked about treatment options.
“Don’t even get me started on the treatments!” Ebola erupted. “They’ve sent courses of monoclonal antibody therapy to Bulape. Mab114! That’s a direct counter to my core value proposition—severe, often fatal illness. They’re making it ‘often not fatal.’ They’re diluting my brand!”
The virus concluded the conference on a note of petulant frustration.
“They’re using expertise from my past outbreaks against me. They’re using science, logistics, and preparedness. It’s a dirty fight. I just want a simple, chaotic outbreak where I can thrive on fear and poor infrastructure. Is that too much to ask?”
“Instead,” Ebola muttered, shutting down its laptop, “I have to deal with professionals.”
